Severe ischemia-reperfusion injury induces epigenetic inactivation of LHX1 in kidney progenitor cells after kidney transplantation.

Autor: Cruzado JM; Department of Nephrology, Hospital Universitari Bellvitge, Barcelona, Spain; Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain; Department of Clinical Sciences, University of Barcelona, Barcelona, Spain. Electronic address: jmcruzado@bellvitgehospital.cat., Sola A; Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain; Nephrology and Dialysis Unit, Meyer Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Florence, Italy; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio,' University of Florence, Florence, Italy., Pato ML; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain; Epigenetic Therapies Group, Genesis of Cancer Program, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain., Manonelles A; Department of Nephrology, Hospital Universitari Bellvitge, Barcelona, Spain; Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain; Department of Clinical Sciences, University of Barcelona, Barcelona, Spain., Varela C; Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain., Setién FE; Cancer Epigenetics Group, Genesis of Cancer Program, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain., Quero-Dotor C; Cancer Epigenetics Group, Genesis of Cancer Program, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain., Heald JS; Epigenetic Therapies Group, Genesis of Cancer Program, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain., Piñeyro D; Cancer Epigenetics Group, Genesis of Cancer Program, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain., Amaya-Garrido A; Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain., Doladé N; Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain., Codina S; Department of Nephrology, Hospital Universitari Bellvitge, Barcelona, Spain; Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain., Couceiro C; Department of Nephrology, Hospital Universitari Bellvitge, Barcelona, Spain; Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain., Bolaños N; Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain., Gomà M; Department of Pathology, Hospital Universitari Bellvitge, Barcelona, Spain., Vigués F; Department of Clinical Sciences, University of Barcelona, Barcelona, Spain; Department of Urology, Hospital Universitari Bellvitge, Barcelona, Spain., Merkel A; Bioinformatics Unit, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain., Romagnani P; Nephrology and Dialysis Unit, Meyer Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Florence, Italy; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio,' University of Florence, Florence, Italy., Berdasco M; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain; Epigenetic Therapies Group, Genesis of Cancer Program, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain. Electronic address: mberdasco@carrerasresearch.org.

Publikováno v: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2024 Nov 07. Date of Electronic Publication: 2024 Nov 07.

Study of the adiabatic absorption process in polymeric hollow fiber membranes for ammonia/water absorption refrigeration systems

Autor: Berdasco, M., Coronas, A., Vallès, M.

Publikováno v: In Applied Thermal Engineering 5 June 2018 137:594-607

Identification of novel NUP98 fusion partners and comutations in acute myeloid leukemia: an adult cohort study.

Autor: Heald JS; Epigenetic Therapies Group, Experimental and Clinical Hematology Program, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., López AM; Hematology Department, Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Pato ML; Epigenetic Therapies Group, Experimental and Clinical Hematology Program, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Ruiz-Xivillé N; Hematology Department, Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Cabezón M; Hematology Department, Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Zamora L; Hematology Department, Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Vives S; Hematology Department, Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Coll R; Hematology Department, Catalan Institute of Oncology-Hospital Universitari Dr. Josep Trueta, Girona, Spain., Maluquer C; Haematology Department, ICO Hospitalet, Hospitalet de Llobregat, Bellvitge Institute for Biomedical Research, Universitat de Barcelona, Barcelona, Spain., Granada I; Hematology Department, Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Solé F; Myelodysplastic Syndromes Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Barcelona, Spain., Esteller M; Cancer Epigenetics Group, Cancer and Leukemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.; Centro de Investigacion Biomedica en Red Cancer, Madrid, Spain., Berdasco M; Epigenetic Therapies Group, Experimental and Clinical Hematology Program, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.

Publikováno v: Blood advances [Blood Adv] 2024 Jun 11; Vol. 8 (11), pp. 2691-2694.

Towards a druggable epitranscriptome: Compounds that target RNA modifications in cancer.

Autor: Berdasco M; Epigenetic Therapies Group, Experimental and Clinical Hematology Program (PHEC), Josep Carreras Leukaemia Research Institute, Barcelona, Spain.; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain., Esteller M; Cancer Epigenetics Group, Cancer and Leukemia Epigenetics and Biology Program (PEBCL), Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2022 Jun; Vol. 179 (12), pp. 2868-2889. Date of Electronic Publication: 2021 Jul 27.

Towards a druggable epitranscriptome: Compounds that target RNA modifications in cancer

Autor: Berdasco, M, Esteller, M

Publikováno v: British Journal of Pharmacology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Epitranscriptomics is an exciting emerging area that studies biochemical modifications of RNA. The field has been opened up by the technical efforts of the last decade to characterize and quantify RNA modifications, and this has led to a map of post-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::9276ee43e60ff09fb25469bfcd717a06
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4740